NBP607-QIV

BIOLOGICAL4 trials

Sponsors

SK Chemicals Co., Ltd., SK Bioscience Co., Ltd.

Conditions

InfluenzaInfluenza, Human

Phase 3

Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

CompletedNCT02467842

SK Chemicals Co., Ltd.Influenza

Start: 2014-10-31End: 2015-05-31Updated: 2020-05-08

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents

CompletedNCT02621164

SK Chemicals Co., Ltd.Influenza, Human

Start: 2014-09-30End: 2015-06-30Updated: 2015-12-03

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

CompletedNCT03020628

SK Chemicals Co., Ltd.Influenza, Human

Start: 2016-10-31End: 2017-06-30Updated: 2017-11-01

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

CompletedNCT03704740

SK Bioscience Co., Ltd.Influenza

Start: 2018-10-25End: 2019-07-12Updated: 2022-05-11

Related Papers

Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.

2017-04-137 citations